source
- Avalyn's upsized IPO; Alector ends another study in GSK partnership🔔 Avalyn Pharma’s $300M IPO: The Boston, MA-based biotech is selling over 16.5 million shares at $18 apiece. The company is set to start trading as {$AVLN} on the Nasdaq Thursday ...Endpoints · 3mo ago↗ source
- Analysts focus on three programs in big year for Bristol MyersWall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pitch. Analysts lobbed questions regarding at least half a dozen trial results expected by…Endpoints · 3mo ago↗ source
- STAT+: Hinge has a new FDA-cleared migraine deviceIn this edition of STAT Health Tech: FDA's plan to use AI to speed up trials, Hinge's new migraine device, and boosting cancer screening with texts.STAT